share_log

Cantor Fitzgerald Maintains Overweight on Soleno Therapeutics, Raises Price Target to $35

Benzinga ·  Sep 26, 2023 10:45

Cantor Fitzgerald analyst Kristen Kluska maintains Soleno Therapeutics (NASDAQ:SLNO) with a Overweight and raises the price target from $19 to $35.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment